FORA Capital LLC Sells 4,074 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• FORA Capital LLC reduced its stake in Alnylam Pharmaceuticals by 32.1%, selling 4,074 shares, and now holds 8,624 shares valued at approximately $2,329,000.
• Multiple institutional investors, including Caisse DE Depot ET Placement DU Quebec and Comerica Bank, significantly increased their holdings in Alnylam, reflecting strong interest in the biopharmaceutical stock.
• Alnylam Pharmaceuticals reported earnings of $0.32 EPS for the last quarter, surpassing analyst expectations, and has a current consensus rating of Moderate Buy among equity research analysts.

FORA Capital LLC cut its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 32.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,624 shares of the biopharmaceutical company's stock after selling 4,074 shares during the quarter. FORA Capital LLC's holdings in Alnylam Pharmaceuticals were worth $2,329,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Alnylam Pharmaceuticals by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock valued at $3,525,544,000 after acquiring an additional 323,206 shares in the last quarter. AQR Capital Management LLC raised its holdings in Alnylam Pharmaceuticals by 60.9% in the 4th quarter. AQR Capital Management LLC now owns 813,356 shares of the biopharmaceutical company's stock valued at $191,391,000 after acquiring an additional 307,702 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new position in Alnylam Pharmaceuticals in the 1st quarter valued at $69,292,000. Price T Rowe Associates Inc. MD raised its holdings in Alnylam Pharmaceuticals by 5.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock valued at $946,466,000 after acquiring an additional 185,783 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in Alnylam Pharmaceuticals by 30,759.4% in the 1st quarter. GAMMA Investing LLC now owns 166,332 shares of the biopharmaceutical company's stock valued at $44,913,000 after acquiring an additional 165,793 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,396 shares of the company's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $632,764.92. Following the sale, the executive vice president owned 22,719 shares in the company, valued at approximately $10,297,841.13. The trade was a 5.79% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Pushkal Garg sold 1,455 shares of the company's stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $458.41, for a total value of $666,986.55. Following the completion of the sale, the executive vice president owned 20,221 shares in the company, valued at $9,269,508.61. This trade represents a 6.71% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 57,594 shares of company stock worth $25,551,456. 1.20% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

ALNY has been the subject of several analyst reports. Wolfe Research raised Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a report on Monday, August 4th. BMO Capital Markets boosted their price target on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an "outperform" rating in a report on Tuesday, June 24th. Truist Financial initiated coverage on Alnylam Pharmaceuticals in a report on Monday, July 21st. They set a "buy" rating and a $385.00 price target for the company. Jefferies Financial Group boosted their price target on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a "buy" rating in a report on Monday, July 7th. Finally, UBS Group boosted their price target on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Twenty-two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $405.33.

Alnylam Pharmaceuticals Price Performance

ALNY stock traded down $5.82 during midday trading on Monday, reaching $446.51. 827,614 shares of the stock were exchanged, compared to its average volume of 1,190,821. The stock has a market capitalization of $58.53 billion, a PE ratio of -180.77 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $469.81. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The company has a fifty day moving average price of $377.23 and a 200 day moving average price of $304.58.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. The business had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.Alnylam Pharmaceuticals's quarterly revenue was up 17.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.